Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionFirst Trust Advisors Lp
Latest Disclosed Ownership382,701 shares
Latest Disclosed Value $ 126,624,127
First Trust Advisors Lp reports 48.94% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - First Trust Advisors Lp filed a 13F-HR form disclosing ownership of 382,701 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $109,337,676 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 256,954 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 48.94% during the quarter. The current value of the position is $99,693,610 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 382,701 125,747 48.94 126,624 23.93 0.0905
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 256,954 46,571 22.14 102,178 6.51 0.0743
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 210,383 -41,434 -16.45 95,935 16.83 0.0713
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 251,817 71,357 39.54 82,115 68.52 0.0660
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 180,460 -147,322 -44.95 48,728 -36.82 0.0432
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 327,782 42,211 14.78 77,130 -1.80 0.0680
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 285,571 45,024 18.72 78,541 34.37 0.0748
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 240,547 23,174 10.66 58,453 79.93 0.0596
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 217,373 -89,320 -29.12 32,486 -44.66 0.0330
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 306,693 73,203 31.35 58,704 41.97 0.0641
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 233,490 -42,886 -15.52 41,351 -21.23 0.0490
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 276,376 -153,711 -35.74 52,495 -39.07 0.0597
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 430,087 9,527 2.27 86,155 -13.80 0.0995
2023-02-09 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 420,560 -74,372 -15.03 99,947 0.89 0.1189
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 494,932 95,067 23.77 99,065 69.86 0.1284
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 399,865 -2,787 -0.69 58,320 -11.30 0.0720
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 402,652 -104,444 -20.60 65,749 -23.54 0.0673
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 507,096 -25,190 -4.73 85,993 -14.44 0.0837
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 532,286 26,363 5.21 100,501 17.18 0.1081
2021-10-12 2021-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 505,923 73,793 17.08 85,764 40.57 0.0928
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 505,923 73,793 85,764 0.0885
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 432,130 -130,495 -23.19 61,012 -16.56 0.0739
2021-02-02 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 562,625 -162,987 -22.46 73,124 -30.79 0.0969
2020-11-05 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 725,612 -83,954 -10.37 105,649 -11.89 0.1692
2020-07-22 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 809,566 -37,668 -4.45 119,905 30.02 0.2078
2020-05-06 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 847,234 249,019 41.63 92,221 33.86 0.2089
2020-02-03 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 598,215 -205,451 -25.56 68,896 6.60 0.1177
2019-11-04 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 803,666 -349,574 -30.31 64,631 -22.76 0.1217
2019-07-30 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,153,240 -39,255 -3.29 83,679 -24.91 0.1578
2019-06-19 2019-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,192,495 14,439 1.23 111,439 29.74 0.2216
2019-05-09 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,192,495 14,439 111,439
2019-02-07 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,178,056 241,031 25.72 85,892 4.74 0.2036
2018-10-25 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 937,025 277,259 42.02 82,008 26.20 0.1527
2018-08-02 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 659,766 123,099 22.94 64,980 1.66 0.1347
2018-04-23 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 536,667 -34,731 -6.08 63,917 -11.96 0.1468
2018-02-08 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 571,398 -213,221 -27.18 72,596 -21.25 0.1728
2017-10-24 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 784,619 158,288 25.27 92,185 84.53 0.2371
2017-08-02 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 626,331 -67,853 -9.77 49,956 40.42 0.1333
2017-05-02 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 694,184 -44,224 -5.99 35,577 28.69 0.0986
2017-02-06 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 738,408 317,432 75.40 27,646 -3.11 0.0823
2016-11-01 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 420,976 3,729 0.89 28,534 23.24 0.0852
2016-08-04 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 417,247 -43,638 -9.47 23,153 -19.97 0.0729
2016-05-10 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 460,885 -762,650 -62.33 28,930 -74.88 0.0929
2016-05-04 2015-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,223,535 -338,836 -21.69 115,184 -8.26 0.2989
2016-02-03 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,223,535 115,184
2015-11-05 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,562,371 6,547 0.42 125,552 -32.68 0.3637
2015-08-04 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,555,824 301,299 24.02 186,497 42.37 0.4840
2015-05-04 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,254,525 396,842 46.27 130,998 57.46 0.3848
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 857,683 857,683 83,195 0.2807
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.